Loading companies…
South Korea · Healthtech · AI · Biotech
A precision-oncology service that tests live cancer cells against drugs and uses clinical data to predict which treatments may work best for each patient.
ImpriMed analyzes a patient's living cancer cells against a panel of anticancer drugs and combines those sensitivity measurements with other biological information. Its AI models use clinical outcome data to predict which medicines are more likely to work, giving oncologists additional evidence when choosing a treatment plan.
The company provides its Drug Response Predictions service to veterinary oncologists treating canine and feline lymphoma and leukemia. It has also developed precision-medicine research programs for human cancers, extending the same strategy of linking ex-vivo drug sensitivity with patient outcomes. The service is used by veterinary hospitals and is supported by a growing clinical-outcomes dataset.
| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series A2 bridge | $10M | LB Investment — LeadAlois Ventures — ParticipantBonAngels — ParticipantHan River Partners — ParticipantNAVER D2SF — ParticipantSamsung Securities — Participant |